221 related articles for article (PubMed ID: 32852559)
21. Cancer is not a risk factor for bullous pemphigoid: 10-year population-based cohort study.
Chen CT; Hu HY; Chang YT; Li CP; Wu CY
Br J Dermatol; 2019 Mar; 180(3):553-558. PubMed ID: 30216411
[TBL] [Abstract][Full Text] [Related]
22. Neurological Cancer is a Risk Factor for Bullous Pemphigoid: 11-Year Population-Based Cohort Study.
Wu CY; Hu HY; Chou YJ; Li CP; Chang YT
Am J Clin Dermatol; 2020 Aug; 21(4):591-597. PubMed ID: 31820332
[TBL] [Abstract][Full Text] [Related]
23. Pemphigoid and cancer.
Lindelöf B; Islam N; Eklund G; Arfors L
Arch Dermatol; 1990 Jan; 126(1):66-8. PubMed ID: 2404464
[TBL] [Abstract][Full Text] [Related]
24. Prevalence and presumptive triggers of localized bullous pemphigoid.
Ständer S; Kasperkiewicz M; Thaçi D; Schmidt E; Zillikens D; Vorobyev A; Ludwig RJ
J Dermatol; 2021 Aug; 48(8):1257-1261. PubMed ID: 33998059
[TBL] [Abstract][Full Text] [Related]
25. Association of bullous pemphigoid with malignancy: A systematic review and meta-analysis.
Atzmony L; Mimouni I; Reiter O; Leshem YA; Taha O; Gdalevich M; Hodak E; Mimouni D
J Am Acad Dermatol; 2017 Oct; 77(4):691-699. PubMed ID: 28645646
[TBL] [Abstract][Full Text] [Related]
26. Risk of solid malignancies in bullous pemphigoid: A large-scale population-based cohort study.
Kridin K; Hammers CM; Ludwig RJ; Cohen AD
J Dermatol; 2021 Mar; 48(3):317-323. PubMed ID: 33368562
[TBL] [Abstract][Full Text] [Related]
27. Bullous pemphigoid associated with the use of dipeptidil peptidase-4 inhibitors: analysis from studies based on pharmacovigilance databases.
Molina-Guarneros JA; Sainz-Gil M; Sanz-Fadrique R; García P; Rodríguez-Jiménez P; Navarro-García E; Martin LH
Int J Clin Pharm; 2020 Apr; 42(2):713-720. PubMed ID: 32140915
[TBL] [Abstract][Full Text] [Related]
28. Psoriasis is associated with increased risk of bullous pemphigoid: A nationwide population-based cohort study in Taiwan.
Ho YH; Hu HY; Chang YT; Li CP; Wu CY
J Dermatol; 2019 Jul; 46(7):604-609. PubMed ID: 31062428
[TBL] [Abstract][Full Text] [Related]
29. A population-based study of the association between bullous pemphigoid and neurologic disorders.
Brick KE; Weaver CH; Savica R; Lohse CM; Pittelkow MR; Boeve BF; Gibson LE; Camilleri MJ; Wieland CN
J Am Acad Dermatol; 2014 Dec; 71(6):1191-7. PubMed ID: 25174542
[TBL] [Abstract][Full Text] [Related]
30. Assessment of Diagnostic Strategy for Early Recognition of Bullous and Nonbullous Variants of Pemphigoid.
Meijer JM; Diercks GFH; de Lang EWG; Pas HH; Jonkman MF
JAMA Dermatol; 2019 Feb; 155(2):158-165. PubMed ID: 30624575
[TBL] [Abstract][Full Text] [Related]
31. Bullous pemphigoid and pemphigus vulgaris--incidence and mortality in the UK: population based cohort study.
Langan SM; Smeeth L; Hubbard R; Fleming KM; Smith CJ; West J
BMJ; 2008 Jul; 337(7662):a180. PubMed ID: 18614511
[TBL] [Abstract][Full Text] [Related]
32. Immunomodulator Galectin-9 is Increased in Blood and Skin of Patients with Bullous Pemphigoid.
Pruessmann J; Pruessmann W; Holtsche MM; Linnemann B; Hammers CM; van Beek N; Zillikens D; Schmidt E; Sadik CD
Acta Derm Venereol; 2021 Mar; 101(3):adv00419. PubMed ID: 33606034
[TBL] [Abstract][Full Text] [Related]
33. The association between neurological diseases, malignancies and cardiovascular comorbidities among patients with bullous pemphigoid: Case-control study in a specialized Polish center.
Kalińska-Bienias A; Kowalczyk E; Jagielski P; Bienias P; Kowalewski C; Woźniak K
Adv Clin Exp Med; 2019 May; 28(5):637-642. PubMed ID: 30784240
[TBL] [Abstract][Full Text] [Related]
34. Psychiatric comorbidity in individuals with bullous pemphigoid and all bullous disorders in the Danish national registers.
Rania M; Petersen LV; Benros ME; Liu Z; Diaz L; Bulik CM
BMC Psychiatry; 2020 Aug; 20(1):411. PubMed ID: 32819315
[TBL] [Abstract][Full Text] [Related]
35. Bullous Pemphigoid: Validation of the National Patient Register in Two Counties in Sweden, 2001 to 2012.
Grönhagen C; Nilzén K; Seifert O; Thorslund K
Acta Derm Venereol; 2017 Jan; 97(1):32-35. PubMed ID: 27171523
[TBL] [Abstract][Full Text] [Related]
36. Association between bullous pemphigoid and psoriasis: Systematic review and meta-analysis of case-control studies.
Phan K; Goyal S; Murrell DF
Australas J Dermatol; 2019 Feb; 60(1):23-28. PubMed ID: 30141189
[TBL] [Abstract][Full Text] [Related]
37. Resolution of bullous pemphigoid and improvement of vitiligo after successful treatment of squamous cell carcinoma of the skin.
Deguchi M; Tsunoda T; Tagami H
Clin Exp Dermatol; 1999 Jan; 24(1):14-5. PubMed ID: 10233641
[TBL] [Abstract][Full Text] [Related]
38. DPP-4 Inhibitors and Increased Reporting Odds of Bullous Pemphigoid: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS) from 2006 to 2020.
Jedlowski PM; Jedlowski MF; Fazel MT
Am J Clin Dermatol; 2021 Nov; 22(6):891-900. PubMed ID: 34287770
[TBL] [Abstract][Full Text] [Related]
39. [A case of lung cancer with bullous pemphigoid].
Takeuchi M; Okazaki A; Nakajima N; Saito Y; Nozaki M; Niibe H
Gan No Rinsho; 1986 May; 32(5):529-33. PubMed ID: 3522956
[TBL] [Abstract][Full Text] [Related]
40. Increased Risk of Bullous Pemphigoid after First-Ever Stroke: A Population-Based Study.
Shen AL; Lin HL; Lin HC; Tseng YF; Hsu CY; Chou CY
Neurodegener Dis; 2017; 17(4-5):166-170. PubMed ID: 28467996
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
